Sanitation: Psychedelic may save nerves from chemo

Health Rounds

By Nancy Lapid, Health Science Editor

Hello Health Rounds readers! Today we feature two early studies, one that points toward a possible way to prevent nerve damage from chemotherapy drugs and another that reveals previously unrecognized effects of bacteria that are known to make adults very sick but that were thought to be harmless to babies.

Among our breaking news stories from the U.S.: Kennedy asked for removal of Pennsylvania measles death from CDC tally; Cyclosporiasis cases in Michigan climb above 14,700; Pentagon temporarily rescinds guidance on testosterone screening for US troops; U.S. sues Kansas school district for aiding transgender students' transitions; and the FDA is working with manufacturers to boost estrogen patch supply amid access concerns.

In the DRC, where the Ebola outbreak has killed more than 3,000: WHO's Tedros says Ebola response must be scaled up; and health officials turn to mobile-phone data to track the outbreak.

Elsewhere: Belgium reports about 3,000 excess deaths over summer due to heat; in Indonesia, more than 1,700 fall sick from free school meals; Ireland health service operator fined for storing data in disused bathroom, turf shed; and India's food warning labels draw fire from all sides.

Industry Updates

US FDA approves Ionis Pharma's rare brain disorder therapy.
Smart ring maker Oura files for US IPO.
Cipla, Qilu partner for US launch of Merck's Keytruda biosimilar.
Haleon secures better shelf space at Walmart, Target.
GoodRx offers health subscription for families.
Ultragenyx Angelman syndrome drug fails late-stage trial.
Nestle to build infant formula plant in Brazil.
Novartis could cut about 130 jobs in Basel site relocation; signs. deal worth up to $3.2 billion for Alteogen's drug delivery technology.
Owkin signs AI drug discovery deal with Boehringer.
Teva's immune disorder drug meets main goal in mid-stage trial.
Aspen bets on manufacturing rebound, obesity drug push.

Childhood obesity in the developing world

REUTERS/Ajeng Dinar Ulfiana

Low and middle-income countries are facing the double burden of a rapid rise in childhood obesity in tandem with stubbornly high rates of undernutrition - and global health organizations and most governments are paying little attention. Read more here.

Study Rounds

Psychedelic drug may prevent chemotherapy nerve damage

The psychedelic drug psilocybin may help prevent the nerve damage that often accompanies chemotherapy, studies in mice suggest.

Chemotherapy-related peripheral neuropathy can result in pain, numbness, increased sensitivity to cold, and loss of sensation that linger long after treatment ends and are often irreversible.

In mice, two doses of psilocybin given before chemotherapy prevented hypersensitivity to cold, protected sensory nerve endings and preserved touch sensation without affecting chemotherapy’s antitumor activity, researchers reported on Thursday in Science.

Psilocybin directly affects the peripheral nervous system through brain cell surface proteins called serotonin 5-HT2A receptors. Blocking the 5-HT2A pathway reversed the drug’s neuroprotective effects, while using a non-hallucinogenic compound that activates the same brain-cell surface proteins produced similar protection to psilocybin.

Psilocybin also helped protect nerve cells’ mitochondria – their “energy factories” – from the damaging effects of chemotherapy drugs, the researchers found.

“There is an urgent need for treatments that prevent nerve injury without interfering with lifesaving chemotherapy,” study leader Dr. Moran Amit of the University of Texas MD Anderson Cancer Center said in a statement. “These findings offer important insights into how psilocybin may protect nerves before damage occurs, rather than treating symptoms after they become persistent.”

His team’s findings are the basis for an upcoming mid-stage trial evaluating psilocybin during chemotherapy in patients with multiple cancer types to determine whether the mechanisms observed in the lab translate to clinically meaningful reductions in peripheral neuropathy in patients.

In babies, C. diff bacteria cause damage without symptoms

“C. diff” infections in infants don’t produce the severe gastrointestinal symptoms the bacteria cause in adults, and so the fact that 40% to 90% of infants in industrialized countries have the organisms in their intestines hasn’t worried doctors – until now.

Without causing symptoms, the Clostridioides difficile bacterium can reshape the developing infant gut and induce changes with long-term consequences, researchers have discovered.

In adults, toxins produced by C. diff cause symptoms ranging from severe diarrhea to fatal colonic inflammation. Around half a million patients are infected in the U.S. annually, resulting in approximately 30,000 fatal cases.

Infants, however, always seemed to be resistant to the effects of the bacterium.

“But… does asymptomatic really mean inconsequential? Could a toxin-producing pathogen actually be reshaping the developing gut without causing obvious symptoms?” study leader Joseph Zackular of Children’s Hospital of Philadelphia (CHOP) said in a statement.

In studies of mice and in lab tests of intestinal biopsy samples from human infants and mini-intestines made from human tissue in test-tubes, the researchers found the presence of C. diff led to remodeling of the epithelium — the layer of cells that line the gut – and reshaping of the immune system that protects the intestines’ moist inner surfaces.

These effects were also observed in the intestines of human infants colonized with C. diff, the researchers reported on Thursday in Science.

“The infant gut epithelium is still building itself, so C. diff doesn't just injure it; it can alter the developmental trajectory of the tissue in ways that may last into adulthood,” study co-author Kathryn Hamilton, also at CHOP, said in a statement.

The authors add that the long-term consequences of these effects need to be studied in more detail.

They also hope to develop a maternal vaccine that would target C. diff, similar to vaccines already in use that immunize mothers to protect newborns against RSV and pertussis.

In case you missed it...

This newsletter was edited by Aurora Ellis.

Sponsors are not involved in the creation of newsletters or other Reuters news content. Advertise in this newsletter or on Reuters' website

Reuters Health Rounds is sent twice a week. Think your friend or colleague should know about us? Forward this newsletter to them. They can also sign up here.

Want to stop receiving this email? Unsubscribe here. To manage which newsletters you're signed up for, click here.

This email includes limited tracking for Reuters to understand whether you’ve engaged with its contents. For more information on how we process your personal information and your rights, please see our Privacy Statement.

Terms & Conditions